Summary
- Ireland’s eighth Disruptive Technologies Innovation Fund call opened on 1 October with €40 million available.
- Projects need at least three partners and must request at least €1.5 million for industrial research or experimental development.
- The scheme couples public funding with commercialisation requirements and private contributions from participating businesses.
Ireland has opened applications for €40 million of collaborative technology funding, adding another round to a programme that has committed more than €530 million to projects spanning artificial intelligence, medical technology, manufacturing, ICT, and environmental technologies since 2018.
The eighth Disruptive Technologies Innovation Fund call is administered by Enterprise Ireland for the Department of Enterprise, Tourism and Employment and will accept applications until 3 February 2027. The €40 million allocation was announced in June, making the 1 October development the opening of the competition rather than a newly created funding pot.
Each proposal must bring together at least three partners, including an SME and another business, while Irish research organisations can participate alongside them. Projects must request at least €1.5 million and can run for up to three years, with funding directed towards industrial research or experimental development rather than early academic work.
Applicants are also expected to show a credible route towards commercialisation. SME partners contribute matched funding, while large companies are required to cover 60% of their eligible project costs, putting a financial commitment behind the claim that the technology has a prospective market.
Funding begins where research becomes expensive
The fund has approved more than €530 million across 131 projects during its first seven calls, with awards averaging roughly €4 million. Previous projects have covered sectors including life sciences, medical devices, artificial intelligence, manufacturing, ICT, and environmental technologies.
The scheme is designed for work that has moved beyond an early research idea but still carries enough technical and commercial uncertainty to make conventional private finance difficult. Consortia are assessed on the technology, development plan, expected economic impact, sustainability, and the ability of participating organisations to deliver together.
Commercialisation is expected over a three to seven year period, extending beyond the funded development phase where necessary. That requirement distinguishes the programme from research support whose primary output may be scientific knowledge or a demonstrator rather than a product capable of reaching customers.
Call 8 also allows Irish semi-state organisations and public bodies to participate as non-funded partners for the first time. They cannot replace the three eligible funded participants, but their involvement could provide access to operating environments, infrastructure, datasets, or prospective users that are difficult to reproduce within a research setting.
A new mandatory eligibility check takes place before the full application, while successful projects are expected to begin within six months of the award announcement. Both changes favour consortia that have resolved ownership, staffing, private funding, and project governance before entering the competition.
Collaboration remains the organising principle
Ireland’s technology economy combines a large multinational presence with domestic companies, universities, research institutes, and public innovation programmes. The fund attempts to connect those groups around development work that no single participant may have the capital, expertise, or infrastructure to undertake alone.
Artificial intelligence illustrates the limits of public technology funding as well as its potential. Irish organisations can build valuable applications, tools, and intellectual property while continuing to depend on foundation models, cloud platforms, chips, and infrastructure supplied by international companies. Commercial success does not necessarily reduce those dependencies.
The same pattern appears in advanced manufacturing and medical technology, where a company can own specialist intellectual property while relying on equipment, software, production systems, or suppliers from other markets. The economic return depends on whether enough of the higher value activity — engineering, ownership, production, sales, and subsequent investment — remains connected to Ireland.
Enterprise Ireland has been holding regional events to help organisations assemble consortia before the February deadline, recognising that collaboration is an eligibility condition rather than an optional feature of the scheme. Smaller companies in particular may possess specialist technology without the research capacity, regulatory expertise, or market access needed to deliver a large programme alone.
No fixed share of the €40 million has been reserved for AI or another technology category, so proposals will compete across fields. The resulting awards will provide a clearer indication of where Ireland sees enough technical ambition and commercial potential to justify public risk sharing, and whether those projects can move beyond funded development into companies and products capable of standing without it.








